Clinical Trials

Uterine Cervical Neoplasms

NCT07216703 2026-04-09

TroFuse-036

Phase 3 Recruiting

1,023 enrolled

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04389632 2026-04-07

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Phase 1 Recruiting

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT06535607 2026-03-24

eVOLVE-02

Phase 2 Recruiting

257 enrolled

GastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04644068 2026-02-19

PETRA

Phase 1/2 Active not recruiting

702 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 2 FDA

BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Phase 1 Recruiting

495 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00980954 2025-12-31

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

236 enrolled 28 charts

Uterine Cervical Neoplasms

NCT04982237 2025-11-19

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

445 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Uterine Cervical Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04016389 2025-08-12

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

Phase NA Recruiting

31 enrolled

Phase NA Not yet recruiting

Uterine Cervical Neoplasms

NCT06977594 2025-06-24

Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

1,000 enrolled

Uterine Cervical Neoplasms, Drug Hypersensitivity, Ovarian Neoplasms, Endometrial Neoplasms

NCT06859775 2025-06-06

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Phase 1/2 Recruiting

100 enrolled

Uterine Cervical Neoplasms, Recurrence

NCT02446652 2025-05-29

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

Phase 3 Withdrawn

Uterine Cervical Neoplasms

NCT06942416 2025-04-24

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Phase 2 Recruiting

36 enrolled

Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, Neoplasms

NCT05179239 2025-04-15

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Phase 3 Terminated

31 enrolled

Uterine Cervical Neoplasms

NCT04868708 2025-03-04

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

50 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Uterine Cervical Neoplasms, Recurrence

NCT06123884 2025-02-10

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Phase 2/3 Recruiting

526 enrolled

Uterine Cervical Neoplasms

NCT03556839 2025-01-08

BEATcc

410 enrolled

Phase 2/3 Enrolling by invitation

Carcinoma, Uterine Cervical Neoplasms

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

510 enrolled

Uterine Cervical Neoplasms

NCT06752135 2024-12-30

HRCC1

Terminated

97 enrolled

Uterine Cervical Neoplasms

NCT01566240 2024-12-05

INTERLACE

500 enrolled

Uterine Cervical Neoplasms

NCT04723875 2024-11-01

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

306 enrolled

Phase 1/2 Active not recruiting

Uterine Cervical Neoplasms

NCT04652076 2024-10-08

GYNET

240 enrolled

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT03367871 2024-06-18

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Phase 2 Terminated

17 enrolled 12 charts

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT06419673 2024-05-17

Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

240 enrolled

Uterine Cervical Neoplasms

NCT06241235 2024-04-02

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Phase 1/2 Recruiting

48 enrolled

Uterine Cervical Neoplasms

NCT04551950 2024-03-08

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Phase 1 Completed

25 enrolled 14 charts

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms, Camurati-Engelmann Syndrome

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

132 enrolled

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT06209294 2024-01-17

Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

Phase 2 Recruiting

30 enrolled

Uterine Cervical Neoplasms

NCT04864782 2024-01-12

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Phase 2/3 Terminated

46 enrolled

Uterine Cervical Neoplasms

NCT05998941 2023-11-22

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 2 Withdrawn

Uterine Cervical Neoplasms

NCT00997009 2023-11-14

MITO CERV 2

108 enrolled

Uterine Cervical Neoplasms

NCT02584478 2023-11-08

AL3818

Phase 3 Unknown

294 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03534713 2023-09-21

ONCOCOL01

Phase 3 Recruiting

310 enrolled

Uterine Cervical Neoplasms

NCT05446883 2022-11-30

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Phase 3 Unknown

498 enrolled

Uterine Cervical Neoplasms

NCT01414608 2022-11-07

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

926 enrolled 13 charts

Uterine Cervical Neoplasms

NCT03834571 2022-06-21

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

Phase 2 Withdrawn

Uterine Cervical Neoplasms, HIV Infections

NCT05384366 2022-05-20

Neoadjuvant Chemotherapy in Cervical Cancer

33 enrolled

Uterine Cervical Neoplasms, Neoplasms

NCT04772001 2022-05-18

Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer

Phase NA Unknown

53 enrolled

Uterine Cervical Neoplasms

NCT05367206 2022-05-10

N6C

Phase 3 Recruiting

280 enrolled

Uterine Cervical Neoplasms

NCT04806945 2022-05-05

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Phase 3 Withdrawn

Uterine Cervical Neoplasms

NCT05151549 2021-12-09

A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

46 enrolled

Uterine Cervical Neoplasms

NCT04974944 2021-10-01

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

172 enrolled

Uterine Cervical Neoplasms

NCT04974827 2021-08-10

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

46 enrolled

Uterine Cervical Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Phase 1 Terminated

41 enrolled

BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03912415 2020-09-18

FERMATA

Phase 3 Unknown

316 enrolled

Uterine Cervical Neoplasms

NCT03852979 2020-01-10

NEOCON-F

Phase 2 Terminated

1 enrolled

Uterine Cervical Neoplasms

NCT01523678 2019-07-10

Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

Phase 2 Completed

108 enrolled